Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. - Wikidata - awgldk - TriplyDB

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

http://www.wikidata.org/entity/Q51972326

about

Alzheimer mechanisms and therapeutic strategies A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention The role of tau in neurodegenerative diseases and its potential as a therapeutic target A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons.Autophagy has a key role in the pathophysiology of schizophrenia Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children Prioritization of neurodevelopmental disease genes by discovery of new mutations.Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein.Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.Activity-dependent neuroprotective protein modulates its own gene expression.Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies.New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia The many faces of tau Genetics and genomics of autism spectrum disorder: embracing complexity.Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease Pharmacotherapeutic targets in Alzheimer's disease New approaches to the treatment of frontotemporal lobar degeneration.Microtubule stabilising peptides rescue tau phenotypes in-vivo.Novel therapeutics based on tau/microtubule dynamics: WO2008084483.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

P2860

Q22252311-2A92A08B-4191-4480-A0C6-B08C5DE4E954 Q24567998-1735A4F1-CBE4-4337-BDA5-918AC74BC7A2 Q26739412-B0A42EA1-C6BC-41B4-983D-AE361347ECB7 Q26865358-92306800-0830-4C0D-A609-6E348B6137B5 Q27005032-13FA732D-DFA6-4811-90A7-F4D7B585038F Q28079929-8DF476AF-26FC-4588-8AB0-923759130D44 Q28304604-1E8F7288-847E-4CAD-BD97-9F4E6C7B2AAC Q30054419-2C3D85CD-FAD9-49E9-8872-D6AC5CCA45A1 Q30540857-49C88673-B61A-4327-B736-470330F7C531 Q31149250-09B63FB0-71CD-4E0C-B37E-0A1467439016 Q33705188-B0A91DF6-1C5D-4F2D-8BA8-BD4D4B74BDD7 Q33707712-A7E2519E-0359-4D2B-BF64-A9C5B87958BB Q33830995-C857602C-F575-4913-8BC7-AC8A34D9E078 Q34055639-15279641-D85A-4551-A8BB-109880BD4C06 Q34064026-D51D2FA7-22A8-400F-B1DC-3D619E0F5CEC Q34190432-877F9D95-6919-489C-865C-878A48B88BF8 Q34292532-EA423A99-B36B-4B98-8326-A82EC971130F Q34330891-689982D8-70AD-4572-BCBD-DB4DF3812454 Q34525286-0190A832-9232-46F0-89F1-0EF00C770D33 Q34612993-2C245295-0248-4372-959E-479E0B1F6A8B Q35653810-9738A041-E44E-4FB3-96F4-F2975BEFA47F Q35852866-54FFB483-FD62-48FB-8D34-1064B8F6BCE7 Q35870359-D4D84F6D-8FD2-42FA-AA87-C15CF008396B Q36363394-6E33C634-1AB1-4FBF-9E3B-4C96CDC5C7B7 Q36460048-DD062A1A-B376-447F-A288-0E0221619702 Q36850555-F695F4F9-7AE7-4995-85B3-E8658B2A0B64 Q36940103-C3F42A12-D333-4709-B578-D8AE12DCF97F Q37295067-6D67206C-E38B-405E-9667-2F58CD641C19 Q37319294-2217803B-139E-481E-8E09-93C5812E2D2E Q37464820-32C6201B-371D-49DF-9B93-AB20A1F4B47D Q37530885-0CD07BB7-2859-4DA8-9037-B2D8517F7E17 Q37841631-1C78D684-8563-47C1-AEFB-87B5A16314D3 Q37910243-2204D1B6-00F2-437C-85A4-9F54F2CA806E Q37986036-B515F06B-4997-4FFE-847F-192266051842 Q38041481-EE555D56-244D-40EC-8418-C15D897F3DD0 Q38286222-BFCBFA8D-5545-4AA6-97F7-8D11F672BF84 Q38636792-8F6973B7-BE20-49C1-B4B5-1FDBBE82B7A7 Q38713424-B9FB2616-CBD4-453B-9C7F-9B702868C147 Q38715233-5C5C0DB5-8A5B-42DF-B131-348D893CFF9D Q38766657-4DD8ECD0-F6AB-448F-A2C5-143777C7F297

P2860

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

http://www.wikidata.org/entity/Q51972326

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@en

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@nl

type

label

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@en

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@nl

prefLabel

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@en

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@nl

P1433

Q51972326-D42C52ED-E140-4496-B5F2-DE88802B909F

P1476

Q51972326-656F0694-7E1E-4F12-80D1-2B9641E96901

P2093

Q51972326-18655934-3730-4021-A9F5-7C9465F3896D

Q51972326-4116ABA0-A3CE-4FE7-92EF-88505C64F665

Q51972326-730DAA2F-B86E-443F-B55D-DD552770A916

Q51972326-94107A08-C1E9-4637-B53B-ADEDE33A4FB4

Q51972326-9431B60B-3762-4936-A2F7-5356E8CB7C5C

Q51972326-DB89F171-FE9D-4F78-A86F-E3BFC8F2529E

P304

Q51972326-03C528C2-DEEF-4D6B-9830-BC19DEE5A55E

P31

Q51972326-46F5C23B-D66E-45FE-A82F-3D1CC0F52AFD

P356

Q51972326-45F19D25-D408-4037-8E86-A63DBA465EE5

P407

Q51972326-77C7FA6E-627F-42F3-ADAA-EF4CB3D55A2C

P433

Q51972326-95D85A6A-9173-4347-94B7-81860221E81C

P478

Q51972326-A12FC1F2-AA27-450D-A8BC-85FA0F07D0DD

P50

Q51972326-18C2BB71-4072-4485-BA81-F2E9D917CF7B

P577

Q51972326-C142761A-F56A-45ED-B20C-856E26B10F56

P5875

Q51972326-02A3B8A4-45BA-468A-B342-53D74C122B80

P698

Q51972326-E8EDEF78-E6AD-49FF-AF01-33B960555326

P356

JPET.107.129551

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Activity-dependent neuroprotec ...... novel transgenic mouse model.

@en

P2093

Illana Gozes

http://www.w3.org/2001/XMLSchema#string

Inna Vulih-Shultzman

http://www.w3.org/2001/XMLSchema#string

Nikolaos Grigoriadis

http://www.w3.org/2001/XMLSchema#string

Olga Touloumi

http://www.w3.org/2001/XMLSchema#string

Shmuel Mandel

http://www.w3.org/2001/XMLSchema#string

Zipora Pittel

http://www.w3.org/2001/XMLSchema#string

P304

438-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.107.129551

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

323

http://www.w3.org/2001/XMLSchema#string

P50

Albert Pinhasov

P577

2007-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6119214

http://www.w3.org/2001/XMLSchema#string

P698

17720885

http://www.w3.org/2001/XMLSchema#string